Therapy / Class: Antibacterial / Rifamycin Class / Non-Systemically Absorbed Antibiotic
Spectrum of Coverage: Active against following pathogens (Including ammonia producing bacteria)
- Non-invasive strains of Escherichia coli spp (entero toxigenic and entero aggregative strains)
- Clostridium spp
- Entero bacteriaceae
- Bacteroides fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus)
- Fusobacterium species
- Eubacterium species
- Peptococcus species
- Pepto streptococcus species
- Gram-negative anaerobes
Mechanism of Action:
Semi-synthetic derivative of rifampin & acts by binding to the beta-sub unit of bacterial DNA-dependent RNA polymerase blocking one of the steps in transcription. This results in inhibition of bacterial protein synthesis & consequently inhibits the growth of bacteria.
Indications:
- Traveller’s Diarrhoea (TD)
- Treatment of Small Intestinal Bacterial Over Growth
- Irritable Bowel Syndrome
Dosage & Administration:
- Travelers’ Diarrhoea (TD): >= 12 years: 600mg/day orally for Traveler’s Diarrhoea.
- Treatment of Small Intestinal Bacterial Over Growth:
- Children 3 to 7 years: 200mg orally 3 times daily for 7 to 10 days
- Children & Adolescents 8 to 17 years: 200 to 550mg orally 3 times daily for 7 to 10 days.
- Irritable Bowel Syndrome: 600mg/day for 7 days
HOW SUPPLIED:
XIFATIC M is available as oral suspension in 60ml Pack.
References:
- J AntimicrobChemother. 2001 Jun;47(6):904-5.
- Therap Adv Gastroenterol. 2011 Jul; 4(4): 227–235.
- European Review for Medical and Pharmacological Sciences, 2013; 17: 1314-1320
Reviews
There are no reviews yet.